Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Part of paid clinical trials in Orange, California.
- Sponsor
- CSL Behring
- Study ID
- NCT07080905
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Hemophilia B
Eligibility Criteria
- Sex
- MALE
- Age
- 138 Months - 206 Months
- Healthy Volunteers
- Not accepted
Interventions
- CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) — GENETICAdministered as a single IV infusion.
Study Details
This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
Key Dates
- First listed
- Jul 23, 2025
- Start date
- Jul 28, 2025
- Status verified
- Aug 2026
- Primary completion
- Oct 24, 2033
- Completion
- Oct 24, 2033
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: CSL222Participants will receive CSL222 as a single intravenous (IV) infusion of 2 × 10\^13 genome copies per kilogram of body weight (gc/kg).
Primary Outcome Measure
Annualized Bleeding Rate (ABR) [ Time Frame: For the Lead-In Period (at least 6 months) and for the 52 weeks after stable FIX expression (months 7 to 18 after treatment with CSL222) ]
Central Contacts
- Trial Registration Coordinator1-610-878-4697
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Center for Inherited Blood Disorders | Orange | California | 92868 | - |
| University of Florida | Gainesville | Florida | 32611 | |
| Arthur M. Blank Hospital - Children's Healthcare of Atlanta | Atlanta | Georgia | 30329 | - |
| University of Michigan Medical Center | Ann Arbor | Michigan | 48109 | |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | - |
Find similar trials in Orange, CA
Related Studies
- Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyPHASE3 · Recruiting · Pfizer · Rancho Cordova, California
- Liver Biopsy Following Gene Therapy For HemophiliaNot Yet Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)Enrolling By Invitation · CSL Behring · Phoenix, Arizona
- Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)PHASE3 · Recruiting · CSL Behring · San Diego, California